114mIn, a candidate for radionuclide therapy: Low-energy cyclotron production and labeling of DTPA-D-Phe-octreotide

Nuclear Medicine and Biology

Volumn 27, Issue 2, 2000, Pages 183-188

  Tolmachev, Vladimir ^a   Bernhardt, Peter ^b   Forssell Aronsson, Eva ^b   Lundqvist, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

114mIn; 114mIn DTPA D Phe1 octreotide; Animal study; Labeling; Production

Indexed keywords

PENTETATE INDIUM 114M; PENTETREOTIDE IN 111; RADIOISOTOPE; UNCLASSIFIED DRUG; CADMIUM; DRUG DERIVATIVE; INDIUM; OCTREOTIDE; PENTETIC ACID; PROTON; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811;

ANIMAL TISSUE; ARTICLE; CYCLOTRON; DRUG DISTRIBUTION; ISOTOPE LABELING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; RADIOACTIVITY; SYNTHESIS; ANIMAL; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALS; CADMIUM RADIOISOTOPES; CYCLOTRONS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, NUDE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; PROTONS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 0033625205     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00096-7     Document Type: Article

References (35)

1. 114mIn via both DTPA and a macrocyclic chelator. J. Nucl. Biol. Med. 36:1992;33-40.
2. 111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma. Targeted Diagn. Ther. 6 73-88.
3. 1-octreotide. In Sixth International Radiopharmaceutical Dosimetry Symposium, Proceedings of a Conference held at Gatlinburg, Tennessee, May 7-10, 1996 (Edited by A. Schlafke-Stelson and E. E. Watson). pp. 127-135. ORISE 99-0164.
4. 111In-DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 35:1994;53-57.
5. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors Synthesis, radiolabeling and in vitro validation . Life Sci. 49:1991;1583-1591.
6. Barendswaard E.C., Scott A.M., Divgi C.R., Williams C. Jr, Coplan K., Riedel E., Yao T.J., Gansow O.A., Finn R.D., Larson S.M., Old L.J., Welt S. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int. J. Oncol. 12:1998;45-53.
7. Otte A., Jermann E., Behe M., Goetze M., Bucher H.C., Roser H.W., Heppeler A., Mueller-Brand J., Maecke H.R. DOTATOC A powerful new tool for receptor-mediated radionuclide therapy . Eur. J. Nucl. Med. 24:1997;792-795.
8. 111In-labelled blood cells. In: Proceedings from the 3rd World Congress of Nuclear Medicine and Biology (Edited by Raynaud C.). Pergamon Press, Oxford, UK.
9. Browne E. and Firestone R. B. (1986) Table of radioactive isotopes. (Edited by Shirley V. S.) John Wiley & Sons, New York.
10. 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts . Nucl. Med. Biol. 20:1993;955-962.
11. Dmitriev P. P. (1986) Radionuclide yield in reactions with protons, deuterons, alpha-particles and helium-3. Handbook. Energoatomizdat, Moscow. (IAEA report INDC(CCP)-263/G+CN+SZ, page 144).
12. Eising E.G., Bier D., Knust E.J., Reiners C. Somatostatinrezeptor-szintigraphie. Methodik, indikationen, ergebnisse. Radiologie. 36:1996;81-88.
13. Fjälling M., Andersson P., Forssell-Aronsson E., Grétarsdóttir J., Johanson V., Tisell L.E., Wängberg B., Nilsson O., Berg G., Michanek A., Lindstedt G., Ahlman H. Systemic radionuclide therapy using indium-111-DTPA-D-Phe-1-octreotide in a patient with midgut carcinoid syndrome. J. Nucl. Med. 37:1996;1519-1521.
14. 1-octreotide in patients with neuroendocrine tumors. In Sixth International Radiopharmaceutical Dosimetry Symposium, Proceedings of a Conference held at Gatlinburg, Tennessee, May 7-10, 1996 (Edited by Schlafke-Stelson A. and Watson E. E.). pp. 643-654. ORISE 99-0164.
15. Halpern S.E. The advantages and limits of indium-111 labeling of antibodies. Experimental studies and clinical applications. Int. J. Rad. Appl. Instrum. [B]. 13:1986;195-201.
16. Halpern S.E., Bartholomew R. Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period. Eur. J. Nucl. Med. 22:1995;1323-1325.
17. Howell R.W., Goddu S.M., Rao D.V. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med. Phys. 25:1998;37-42.
18. ICRU Report 49 D (1994) Stopping Powers and Ranges for Protons and Alpha. Bethesda, MD 20814-3095.
19. Kairemo K.J., Ramsay H.A., Tagesson M., Jekunen A.P., Paavonen T.K., Jaaskela-Saari H.A., Liewendahl K., Ljunggren K., Savolainen S., Strand S.-E. Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer - Dosimetric and biokinetic aspects. Eur. J. Nucl. Med. 23:1996;631-638.
20. Khaw B.A., Cooney J., Edgington T., Strauss H.W. Differences in experimental tumor localization of dual-labeled monoclonal antibody. J. Nucl. Med. 27:1986;1293-1299.
21. Kosmas C., Kalofonos H.P., Hird V., Epenetos A. Monoclonal antibody targeting of ovarian carcinoma. Oncology. 55:1998;435-446.
22. 3]-octreotide The Rotterdam experience with more than 1000 patients . Eur. J. Nucl. Med. 20:1993;716-731.
23. 1]-octreotide. A case history. In: Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease (Edited by Wiedenmann B., Kvols L. K., Arnold R. and Rieken E. O.) Ann NY Acad Sci, 733, 496-506.
24. Krenning E. P., Kooij P. P. M. and Pauwels S. (1996) Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 57(suppl 1), 57-61.
25. 111In-DTPA-D-Phe-1-octreotide in patients. In Sixth International Radiopharmaceutical Dosimetry Symposium, Proceedings of a Conference held at Gatlinburg, Tennessee, May 7-10, 1996 (Edited by Schlafke-Stelson A. and Watson E. E.). pp. 631-642.
26. Li M., Meares C.F. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug. Chem. 4:1993;275-283.
27. 110In - a new generator system for positron emission tomography. Int. J. Rad. Appl. Instrum. [A]. 42:1991;447-450.
28. 110In from enriched Cd targets by the thermal diffusion. Appl. Radiat. Isot. 46:1995;859-863.
29. Marcus C.S., Stabin M.G., Watson E.E., Kuperus J.H. Contribution of contaminant indium-114m/indium-114 to indium-111 oxine blood dosimetry. J. Nucl. Med. 26:1985;1091-1093.
30. Mughabghab S. F., Divadeenam M. and Holden N. E. (1981) Neutron Cross Sections. Vol. 1. Neutron Resonance Parameters and Thermal Cross Sections. Academic Press, New York.
31. Press O.W., Shan D., Howell-Clark J., Eary J., Appelbaum F.R., Matthews D., King D.J., Haines A.M., Hamann P., Hinman L., Shochat D., Bernstein I.D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56:1996;2123-2129.
32. Sharma H.L., Cowan R.A., Crowther D. Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytes. Anticancer Res. 17:1997;1815-1821.
33. Shih L.B., Thorpe S.R., Griffiths G.L., Diril H., Ong G.L., Hansen H.J., Goldenberg D.M., Mattes M.J. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro A comparison of nine radiolabels . J. Nucl. Med. 35:1994;899-908.
34. Tolmachev V., Lundqvist H. Rapid separation of gallium from zinc targets by thermal diffusion. Appl. Radiat. Isot. 47:1996;297-299.
35. Zweit J. Radionuclides and carrier molecules for therapy. Phys. Med. Biol. 41:1996;1905-1914.